A
Alphyn Biologics
Develops first-in-class, multi-target therapeutics for atopic dermatitis and other severe and common skin diseases
About Alphyn Biologics
Alphyn Biologics is a life science company focused on developing a new class of drugs called Multi Target therapies to treat severe and prevalent skin diseases. The company leverages its patent-pending AB 101 platform biomaterial, which contains multiple bioactives, to address complex skin conditions. Alphyn's primary target is Atopic Dermatitis (AD), also known as Eczema, a condition that affects millions globally and is notoriously difficult to treat. The AB 101 platform aims to tackle all aspects of AD, including immune response issues like inflammation and itch, as well as bacterial problems such as infections and MRSA drug-resistant bacteria.
Alphyn Biologics operates in the pharmaceutical and biotechnology market, serving patients with severe skin conditions. The company follows a business model centered on research and development, aiming to bring innovative treatments to market through FDA approval processes. Revenue is generated through the commercialization of its proprietary therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Annapolis Neck, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 57.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2025 | $25M | $100M | QCA Ventures | ↗ |
| EARLY VC✓Equity / VC | Mar 2024 | $5.2M | $21M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Alphyn Biologics is 740 monthly website visits, down 38.3% over the last three months. Alphyn Biologics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alphyn Biologics in the Annapolis Neck ecosystem
The Alphyn Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
QCA Ventures
Serial Stage Venture Partners
Angel Physician Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alphyn Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alphyn Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








